Angiotensin-(1-7) blockade attenuates captopril- or hydralazine-induced cardiovascular protection in spontaneously hypertensive rats treated with NG-nitro-l-arginine methyl ester

Journal of Cardiovascular Pharmacology

Volumn 57, Issue 5, 2011, Pages 559-567

  Benter, Ibrahim F ^a   Yousif, Mariam H M ^a   Al Saleh, Fatemah M ^a   Raghupathy, Raj ^a   Chappell, Mark C ^b,c   Diz, Debra I ^b  

^a KUWAIT UNIVERSITY   (Kuwait)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c Hypertension and Vascular Research Center   (United States)

Author keywords

A 779; heart; hydralazine; ischemia; nitric oxide

Indexed keywords

ANGIOTENSIN[1-7]; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; CAPTOPRIL; HYDRALAZINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEART PROTECTION; HYPERTENSION; ISOLATED HEART; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; BRAIN; CAPTOPRIL; CYTOKINES; HEART; HYDRALAZINE; HYPERTENSION; INSULIN; KIDNEY; LEPTIN; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL REPERFUSION INJURY; NG-NITROARGININE METHYL ESTER; PEPTIDE FRAGMENTS; PERFUSION; PROTEINURIA; RATS; RATS, INBRED SHR; VENTRICULAR FUNCTION, LEFT;

EID: 79957668948     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31821324b6     Document Type: Article

References (42)

1. Chappell MC. Emerging evidence for a functional angiotesin-converting enzyme 2-angiotensin-(1-7) mas receptor axis; more than regulation of blood pressure? Hypertension. 2007;50:596-599 (Pubitemid 47442717)
2. Ferrario CM. Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. Hypertension. 2006;47:515-521 (Pubitemid 43843868)
3. Santos RA, Ferreira AJ, Simoes e Silva AC. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol. 2008;93:519-527 (Pubitemid 351595060)
4. Shaltout HA, Westwood B, Averill DB, et al. Angiotensin metabolism in renal proximal tubules, urine and serum of sheep: evidence for ACE2- dependent processing of Angiotensin II. Am J Physiol Renal Physiol. 2006;292:F82-F91 (Pubitemid 46105246)
5. Allred AJ, Diz DI, Ferrario CM, et al. Pathways for angiotensin-(1-7) metabolism in pulmonary and renal tissues. Am J Physiol. 2000;279: F841-F850
6. Yamamoto K, Chappell MC, Brosnihan KB, et al. In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension. 1992;19:692-696
7. Santos RAS, Brosnihan KB, Jacobsen DW, et al. Production of angiotensin-(1-7) by human vascular endothelium. Hypertension. 1992; 19(Suppl II):56-61
8. Garabelli PJ, Modrall JG, Penninger JM, et al. Distinct roles for angiotensin converting enzyme 2 and carboxypeptidase A in the processing of angiotensins in the murine heart. Exp Physiol. 2008;93:613-621 (Pubitemid 351595064)
9. Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA. 2003;100:8258-8263 (Pubitemid 36842532)
10. Sampaio WO, Henrique de CC, Santos RA, et al. Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension. 2007;50:1093-1098 (Pubitemid 350172931)
11. Gwathmey TM, Westwood BM, Pirro NT, et al. The nuclear angiotensin- (1-7) receptor is functionally coupled to the formation of nitric oxide. Am J Physiol Renal Physiol. 2010;299:F983-F990
12. Iyer SN, Chappell MC, Yamada K, et al. Endogenous inhibition of angiotensin-(1-7) reverses the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension. 1997;309:477-483
13. Iyer SN, Averill DB, Chappell MC, et al. Contribution of angiotensin-(1-7) to blood pressure regulation in salt-depleted hypertensive rats. Hypertension. 2000;36:417-422
14. Iyer SN, Yamada K, Diz DI, et al. Evidence that prostaglandins mediate the antihypertensive actions of angiotensin-(1-7) during chronic blockade of the renin-angiotensin system. J Cardiovasc Pharmacol. 2000;36:109-117 (Pubitemid 30419130)
15. Ferrario CM, Jessup JA, Gallagher PE, et al. Effects of renin angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int. 2005;68:2189-2196
16. Iyer SN, Chappell MC, Averill DB, et al. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension. 1998;31:699-705
17. Mancini GBJ, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (trial on reversing ENdothelia dysfunction) study. Circulation. 1996;94:258-265 (Pubitemid 26266107)
18. Igase M, Strawn WB, Gallagher PE, et al. Vascular AT1 receptors but not arterial pressure regulate ACE2 expression in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2005;289:H1013-H1019 (Pubitemid 41208941)
19. Loot AE, Roks AJM, Henning RH, et al. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation. 2002;105:1548-1550 (Pubitemid 34297630)
20. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822-828 (Pubitemid 34670323)
21. Benter IF, Yousif MHM, Cojocel C, et al. Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am J Physiol Heart Circ Physiol. 2006;292:H666-H672
22. Benter IF, Yousif MHM, Anim JT, et al. Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Am J Physiol Heart Circ Physiol. 2006;290:H684-H691
23. Benter IF, Yousif MH, Dhaunsi GS, et al. Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am J Nephrol. 2008;28:25-33 (Pubitemid 350126490)
24. Pendergrass KD, Pirro NT, Westwood BM, et al. Sex differences in circulating and renal angiotensins of hypertensive mRen(2). Lewis but not normotensive Lewis rats. Am J Physiol Heart Circ Physiol. 2008;295: H10-H20
25. Strawn WB, Ferrario CM, Tallant EA. Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension. 1999;33(pt II): 207-211 (Pubitemid 29065661)
26. van der Wouden EA, Henning RH, Deelman LE, et al. Does angiotensin (1-7) contribute to the anti-proteinuric effect of ACE-inhibitors? J Renin Angiotensin Aldosterone Syst. 2005;6:96-101 (Pubitemid 41699980)
27. Wang Y, Qian C, Roks AJ, et al. Circulating rather than cardiac angiotensin-(1-7) stimulates cardioprotection after myocardial infarction. Circ Heart Fail. 2010;3:286-293
28. Zeng W, Chen W, Leng X, et al. Chronic angiotensin-(1-7) administration improves vascular remodeling after angioplasty through the regulation of the TGF-beta/Smad signaling pathway in rabbits. Biochem Biophys Res Commun. 2009;389:138-144
29. Grobe JL, Mecca AP, Mao H, et al. Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol. 2006;290:H2417-H2423 (Pubitemid 43846070)
30. Shenoy V, Ferreira AJ, Qi Y, et al. The angiotensin-converting enzyme 2/ angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med. 2010;182:1065-1072
31. Grobe JL, Der SS, Stewart JM, et al. ACE2 overexpression inhibits hypoxia-induced collagen production by cardiac fibroblasts. Clin Sci (Lond). 2007;113:357-364 (Pubitemid 47572276)
32. Cook KL, Metheny-Barlow LJ, Tallant EA, et al. Angiotensin-(1-7) reduces fibrosis in orthotopic breast tumors. Cancer Res. 2010;70: 8319-8328
33. Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension. 1996;27: 523-528
34. Ren Y, Garvin JL, Carretero OA. Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension. 2002;39:799-802
35. Gwathmey TM, Shaltout HA, Pendergrass KD, et al. Nuclear angiotensin II type 2 (AT2) receptors are functionally linked to nitric oxide production. Am J Physiol Renal Physiol. 2009;296:F1484-F1493
36. Sampaio WO, dos Santos RA, Faria-Silva R, et al. Angiotensin-(1-7) through receptor mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension. 2007;49:185-192 (Pubitemid 46360359)
37. Munzel T, Kurz S, Rajagopalan S, et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest. 1996;98: 1465-1470 (Pubitemid 26322073)
38. Vidrio H, Gonzalez-Romo P, Alvarez E, et al. Hydralazine decreases sodium nitroprusside-induced rat aortic ring relaxation and increased cGMP production by rat aortic myocytes. Life Sci. 2005;77:3105-3116 (Pubitemid 41423746)
39. Vidrio H, Fernandez G, Medina M, et al. Effects of hydrazine derivatives on vascular smooth muscle contractility, blood pressure and cGMP production in rats: comparison with hydralazine. Vascul Pharmacol. 2003; 40:13-21 (Pubitemid 36398222)
40. Daiber A, Oelze M, Coldewey M, et al. Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. Biochem Biophys Res Commun. 2005;338:1865-1874 (Pubitemid 41643103)
41. Wei S, Kasuya Y, Yanagisawa M, et al. Studies on endothelium-dependent vasorelaxation by hydralazine in porcine coronary artery. Eur J Pharmacol. 1997;321:307-314 (Pubitemid 27105933)
42. De Mello WC, Ferrario CM, Jessup JA. Beneficial versus harmful effects of Angiotensin (1-7) on impulse propagation and cardiac arrhythmias in the failing heart. J Renin Angiotensin Aldosterone Sys. 2007;8:74-80 (Pubitemid 47272470)